BioLife Solutions, Inc.

01/09/2026

📣 Did you hear? Phacilitate Advanced Therapies Week 2026 is being held on February 9-12 instead of in January, and in San Diego instead of in Miami this year.

Come connect with the BioLife team at booth 420 – Todd Berard, Sandy Jones, Bill Yang, Vicky Tran, Andrew Sabatier, and Amy Ma will be onsite. We can’t wait for you to see our new booth display.

We’re here to catch up and discuss your biopreservation and cell processing successes and challenges.

Make your plans to America’s Finest City soon! ☀️🌊🦭

https://www.phacilitate.com/advanced-therapies-week

Are you a therapeutic/drug developer with an active clinical or pre-clinical pipeline? Request a FREE pass here:
https://forms.reg.buzz/advanced-therapies-week-2026/?exhibitor-inviter=biolife-solutions&badge-type=ad0f5158-2cda-11f0-a526-000000000000×tamp=1796929689&signature=NjUwODY3ZWNhZDFkYmRiOWE3OWY2ZDk0MDY1MzNiYmQ3NzQ3MDIwZQ%3D%3D

12/31/2025

We’d like to wish all our customers, suppliers, investors, and team members a Happy New Year! 🎆

We are grateful for your dedication, efforts, and passion to move the advanced therapies field forward.

Here’s to an amazing and prosperous 2026! ✨👏

12/29/2025

We’re thrilled to announce we are sponsoring and exhibiting at Phacilitate Advanced Therapies Week 2026 in the beautiful, warm, and sunny city of San Diego, CA. ☀️🏝️

Join us at booth 420 to see how we can work together to optimize your workflow.

Let’s talk about your biopreservation media and reagents, storage containers, fill & finish systems, and your thawing procedure. We have unique technologies to preserve and save your cells.

Don’t miss out on this innovative cell and gene therapy event!

👉 Learn more and register soon:
https://www.phacilitate.com/advanced-therapies-week

🎯 Are you a therapeutic/drug developer with an active clinical or pre-clinical pipeline?
Request your free pass here:
https://forms.reg.buzz/advanced-therapies-week-2026/?exhibitor-inviter=biolife-solutions&badge-type=ad0f5158-2cda-11f0-a526-000000000000×tamp=1796929689&signature=NjUwODY3ZWNhZDFkYmRiOWE3OWY2ZDk0MDY1MzNiYmQ3NzQ3MDIwZQ%3D%3D

12/26/2025

As 2025 wraps up, we’d like to share our last three blog posts if you’re in need of some ‘quiet reading time’ after all the holiday events.

🔥 September: The Silent Threat in Cell Therapy Development: Transient Warming Events

🧪 October: Biopreservation Is Critical. Start with the Team That Wrote the Playbook.

🤝 November: Preserving the Promise™—Together

Check them out and let us know what you think:

BioLife Solutions Insights

12/22/2025

The BioLife Solutions team wishes everyone a wonderful and festive holiday season these last two weeks of the year. 🎀❄️

We hope you find time to relax and enjoy your loved ones. See you in 2026!

12/19/2025

BioLife incorporates ice recrystallization inhibitors (IRIs) into cryopreservation workflows and reduces recrystallization-driven injury and variability.

12/18/2025

🌟 Friendly Reminder 🌟

BioLife Solutions offices are closed from Monday, December 22, 2025, through Friday, January 2, 2026.

We’ve had an amazing year, and we want to show our gratitude and appreciation to our team members, vendors, and customers by taking a well-deserved holiday break.

Operations and shipping of products will resume on Monday, January 5. We will come back refreshed and ready to assist you in 2026.

Happy Holidays to all! 🎁

12/18/2025

Our October 9 webinar, “Closing the loop: eliminating open handling risks in CGT manufacturing,” with Cell & Gene Therapy Insights is available now as an article.

🔗 Erik Woods of Health, Jon Pileggi of CTMC, and Sean Werner of BioLife Solutions, outline how transitioning from open, manual manufacturing to fully closed-system processing and closed cryogenic storage significantly improves the scalability, cost efficiency, and sterility of cell and gene therapy production.

🔗 Closed, single-use technologies are essential infrastructure for compliant and economically viable CGT manufacturing at commercial scale.

Review the data, comparative models, and the results from a CAR-T case study. 📊

https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3701/closedsystem-process-optimization-for-cgt-manufacturing-and-storage

12/17/2025

AABB recently released the 4th Edition of Apheresis: Principles and Practice, Volume 3: Cellular Therapy Apheresis.

❄️ Chapter 7, “The Cryopreservation of Apheresis Products in Cell Therapy,” features contributions from Dr. Jason Acker and colleagues at the University of Alberta.

❄️ This chapter provides a comprehensive overview of the science, current practices, limitations, and emerging innovations related to the cryopreservation of apheresis-derived blood products used in transfusion medicine and cell therapy manufacturing.

❄️ Dr. Acker and team emphasize that although cryopreservation is mature as a scientific discipline, its translation into clinical practice is inconsistent, and significant optimization opportunities remain—particularly for stem cell and adoptive cell therapies (CAR-T, TIL, etc.) where cryopreservation is operationally essential.

Check out an overview of Volume 3 and make sure to order your print copy today! 📖

https://www.aabb.org/aabb-store/product/apheresis-principles-and-practice-4th-ed-volume-3-cellular-therapy-apheresis-print-19510136

12/12/2025

About a month ago, we released The Cell Summit ’25 Proceedings eBook with Genetic Engineering & Biotechnology News (GEN).

💡 If you missed it, this eBook provides actionable takeaways from speakers at The Cell Summit ’25 event that we hosted in Indianapolis from August 5-6, 2025. The Cell Summit focused on cell and gene therapy manufacturing solutions, best practices, process optimizations, and innovative technologies.

💡 The eBook features contributions from our co-sponsors Azenta Life Sciences, Entegris, and part of our scientific bench - Alireza Abazari, Sean Werner, Jason Acker, and Robert Ben.

We’re already planning for The Cell Summit ’26!

💻 Download the eBook for CGT insights: https://promo.genengnews.com/biolife-cell-summit-25-proceedings/

12/09/2025

Cell and gene therapies (CGTs) are advancing rapidly, but their success hinges on maintaining the integrity of living cells throughout manufacturing, storage, distribution, and at the patient point-of-care.

� An often-overlooked threat is transient warming events (TWEs). These are brief temperature excursions that can silently damage cryopreserved cells. Even short-lived warming events can trigger biological stress leading to delayed onset cell death and loss of therapeutic potency.

� In a recent article with HIT Consultant Media, Dr. Jason Acker of Panthera CryoSolutions, part of BioLife Solutions, states that when CGTs scale commercially and move across multiple sites, TWEs become a critical operational and patient-safety risk.

How do we reduce the risk of TWEs�
Dr. Acker advises on proactive measures that can be taken to ensure consistent, safe, and commercially viable delivery of high-value therapies.

� Read on for solutions to TWE challenges: https://hitconsultant.net/2025/12/02/transient-warming-events-twes-the-silent-threat-to-cell-and-gene-therapy-integrity/

12/04/2025

To celebrate their 10th anniversary and 10 strong years of new advanced therapy developments, Cell & Gene Therapy Insights created an infographic highlighting some of the major CGT breakthroughs and milestones.

We’re proud to support these brilliant organizations, with BioLife’s biopreservation media and cryogenic storage vials being utilized in almost half of the therapies shared in this infographic.

We’ve seen the industry transform from basic research to preliminary trials to final regulatory body approvals, globally.

As winter holidays approach, we invite you to celebrate these achievements for patients with us!

Download the infographic: https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3613/a-decade-of-breakthroughs-10-years-of-cell-gene-therapy